Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines. Its approved drug INPEFA (sotagliflozin) reduces cardiovascular death risk in heart failure patients. It is developing sotagliflozin for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, pilavapadin for neuropathic pain, and LX9851 for obesity, the latter licensed exclusively to Novo Nordisk. The company uses gene knockout technologies to identify drug targets.
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001062822-26-000050 | EDGAR | 49K words |
| 2025-03-07 | 2024-12-31 | 0001062822-25-000013 | EDGAR | 49K words |
| 2024-03-25 | 2023-12-31 | 0001062822-24-000008 | EDGAR | 48K words |
| 2023-03-03 | 2022-12-31 | 0001062822-23-000007 | EDGAR | 53K words |
| 2022-03-10 | 2021-12-31 | 0001062822-22-000005 | EDGAR | 53K words |
| 2021-03-12 | 2020-12-31 | 0001062822-21-000013 | EDGAR | 58K words |
| 2020-03-12 | 2019-12-31 | 0001062822-20-000015 | EDGAR | 60K words |
| 2019-03-15 | 2018-12-31 | 0001062822-19-000007 | EDGAR | 65K words |
| 2018-03-01 | 2017-12-31 | 0001062822-18-000008 | EDGAR | 61K words |
| 2017-03-06 | 2016-12-31 | 0001062822-17-000013 | EDGAR | 56K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001062822-26-000117 | EDGAR | 14K words |
| 2025-11-06 | 2025-09-30 | 0001062822-25-000054 | EDGAR | 14K words |
| 2025-08-06 | 2025-06-30 | 0001628280-25-038340 | EDGAR | 14K words |
| 2025-05-14 | 2025-03-31 | 0001062822-25-000029 | EDGAR | 14K words |
| 2024-11-13 | 2024-09-30 | 0001062822-24-000060 | EDGAR | 13K words |
| 2024-08-02 | 2024-06-30 | 0001062822-24-000046 | EDGAR | 13K words |
| 2024-05-02 | 2024-03-31 | 0001062822-24-000024 | EDGAR | 12K words |
| 2023-11-08 | 2023-09-30 | 0001062822-23-000058 | EDGAR | 14K words |
| 2023-08-04 | 2023-06-30 | 0001062822-23-000047 | EDGAR | 14K words |
| 2023-05-04 | 2023-03-31 | 0001062822-23-000024 | EDGAR | 14K words |
| 2022-11-09 | 2022-09-30 | 0001062822-22-000042 | EDGAR | 14K words |
| 2022-08-03 | 2022-06-30 | 0001062822-22-000035 | EDGAR | 14K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001062822-26-000112 | EDGAR | 2K words |
| 2026-03-05 | 0001062822-26-000047 | EDGAR | 2K words |
| 2026-02-02 | 0001193125-26-033793 | EDGAR | 1K words |
| 2026-01-29 | 0001193125-26-029514 | EDGAR | 1K words |
| 2025-11-10 | 0001193125-25-274383 | EDGAR | 1K words |
| 2025-11-06 | 0001193125-25-270020 | EDGAR | 1K words |
| 2025-11-06 | 0001062822-25-000049 | EDGAR | 2K words |
| 2025-08-06 | 0001062822-25-000042 | EDGAR | 2K words |
| 2025-07-28 | 0001062822-25-000037 | EDGAR | 0K words |
| 2025-07-03 | 0001062822-25-000035 | EDGAR | 1K words |
303 total filings indexed. 271 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001062822 |
| Ticker | LXRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | The Woodlands, Texas |
| Website | https://www.lexpharma.com |
| Listed | 2000-04-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/LXRX (~200 tokens, structured JSON with cryptographic provenance)